Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus

Desensitization may permit the continued use of amprenavir in HIV-positive patients with a history of amprenavir-induced maculopapular eruptions who have limited alternate treatment options.